Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell-like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. METHODS: We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. RESULTS: and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on "chronic active" B-cell receptor signaling that is amenable to therapeutic inhibition. CONCLUSIONS: We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“LBCL is genetically and biologically heterogeneous. This diversity includes both tumor and the corresponding tumor microenvironment (TME), and it affects response to standard immunochemotherapy.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationRosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationStromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationA loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationInhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Self-citationChalla-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
Cited by
Items 201–300 of 1,000
Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies
Kennedy, R., & Klein, U. (2018) · Cells · doi:10.3390/cells7110189 · Cited by 64
Frontline treatment of diffuse large B‐cell lymphoma: Beyond R‐CHOP
Mondello, P., & Mian, M. (2019) · Hematological Oncology · doi:10.1002/hon.2613 · Cited by 63
The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma
Eluard, B., Nuan-Aliman, S., Faumont, N., Collares, D., Bordereaux, D., Montagne, A., Martins, I., Cagnard, N., Caly, M., Taoui, O., et al. (2021) · Blood · doi:10.1182/blood.2020010039 · Cited by 63
Nie, T., Liu, H., Fang, Z., Zheng, Y., Zhang, R., Xu, X., Liu, S., & Wu, J. (2023) · ACS Nano · doi:10.1021/acsnano.3c02803 · Cited by 63
Cai, Y., Lv, L., Lu, T., Ding, M., Yu, Z., Chen, X., Zhou, X., & Wang, X. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01475-1 · Cited by 63
Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets
Miao, Y., Medeiros, L. J., Xu-Monette, Z. Y., Li, J., & Young, K. H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00107 · Cited by 63
The role of oncogenic Notch2 signaling in cancer: a novel therapeutic target.
Xiu, M., & Liu, Y. (2019) · PubMed · Cited by 63
Collinge, B. J., Ben‐Neriah, S., Chong, L. C., Boyle, M., Jiang, A., Miyata‐Takata, T., Farinha, P., Craig, J. W., Slack, G. W., Ennishi, D., et al. (2020) · Blood · doi:10.1182/blood.2020007193 · Cited by 63
Self-citationBarišić, D., Chin, C. R., Meydan, C., Teater, M. R., Tsialta, I., Mlynarczyk, C., Chadburn, A., Wang, X., Sarkozy, M., Xia, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.010 · Cited by 62
New Insights into Diffuse Large B-Cell Lymphoma Pathobiology
Solimando, A. G., Annese, T., Tamma, R., Ingravallo, G., Maiorano, E., Vacca, A., Specchia, G., & Ribatti, D. (2020) · Cancers · doi:10.3390/cancers12071869 · Cited by 61
Frauenfeld, L., de Anta, N. C., Ramis-Zaldivar, J. E., Streich, S., Salmerón‐Villalobos, J., Otto, F., Mayer, A., Steinhilber, J., Pinyol, M., Mankel, B., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006034 · Cited by 61
Self-citationLiu, Z., Filip, I., Gómez, K., Engelbrecht, D., Meer, S., Lalloo, P. N., Patel, P., Perner, Y., Zhao, J., Wang, J., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0051 · Cited by 62
Self-citationLiu, T., Lam, V., Thieme, E., Sun, D., Wang, X., Xu, F., Wang, L., Danilova, O. V., Xia, Z., Tyner, J. W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0464 · Cited by 60
Large B cell lymphoma microenvironment archetype profiles
Li, X., Singhal, K., Deng, Q., Chihara, D., Russler‐Germain, D. A., Harkins, R. A., Henderson, J. M., Arita, K., Kizhakeyil, A., Sun, R., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.002 · Cited by 61
Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14
Choi, J., Phelan, J. D., Wright, G. W., Häupl, B., Huang, D. W., Shaffer, A. L., Young, R. M., Wang, Z., Zhao, H., Yu, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921187117 · Cited by 60
Self-citationAdaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas
Reimann, M., Schrezenmeier, J., Richter-Pechanska, P., Dolnik, A., Hick, T. P., Schleich, K., Cai, X., Fan, D. N. Y., Lohneis, P., Maßwig, S., et al. (2021) · Blood · doi:10.1182/blood.2020005244 · Cited by 59
Self-citationSingle-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma
Colombo, A., Hav, M., Singh, M. P., Xu, A. M., Gamboa, A., Lemos, T., Gerdtsson, E., Chen, D., Houldsworth, J., Shaknovich, R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007493 · Cited by 59
Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
Zhang, J., Gu, Y., & Chen, B. (2023) · Cancer Management and Research · doi:10.2147/cmar.s400013 · Cited by 59
2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma
Tavakkoli, M., & Barta, S. K. (2023) · American Journal of Hematology · doi:10.1002/ajh.27075 · Cited by 59
Sheng, L., Zhang, Y., Song, Q., Jiang, X., Cao, W., Li, L., Yi, H., Weng, X., Chen, S., Wang, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298815 · Cited by 59
How cancer genomics is transforming diagnosis and treatment
Nogrady, B. (2020) · Nature · doi:10.1038/d41586-020-00845-4 · Cited by 59
Hong, Y., Ren, T., Wang, X., Liu, X., Fei, Y., Meng, S., Han, X., Sun, C., Shen, H., Li, L., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01634-w · Cited by 58
Self-citationNon-specific orbital inflammation: Current understanding and unmet needs
Lee, M. J., Planck, S. R., Choi, D., Harrington, C. A., Wilson, D. J., Dailey, R. A., Ng, J. D., Steele, E. A., Hamilton, B. E., Khwarg, S. I., et al. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100885 · Cited by 58
Aoki, T., Jiang, A., Xu, A. M., Yin, Y., Gamboa, A., Milne, K., Takata, K., Miyata‐Takata, T., Chung, S., Rai, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01115 · Cited by 58
Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation
Müschen, M. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0154-3 · Cited by 58
Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma
Wu, X., Stenson, M. J., Abeykoon, J. P., Nowakowski, K. E., Zhang, L., Lawson, J., Wellik, L. E., Li, Y., Krull, J. E., Wenzl, K., et al. (2019) · Blood · doi:10.1182/blood.2018874560 · Cited by 58
Zhang, M., Fang, Y., Wang, L., Cheng, S., Fu, D., He, Y., Zhao, Y. F., Wang, C.-F., Jiang, X., Song, Q., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00948-9 · Cited by 58
Self-citationDreval, K., Hilton, L. K., Cruz, M., Shaalan, H., Ben‐Neriah, S., Boyle, M., Collinge, B. J., Coyle, K. M., Duns, G., Farinha, P., et al. (2023) · Blood · doi:10.1182/blood.2022018719 · Cited by 57
Self-citationUnraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
González‐Rincón, J., Méndez, M., Gómez, S., García, J. F., Martín, P., Bellas, C., Pedrosa, L., Rodríguez-Pinilla, S. M., Camacho, F. I., Quero, C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212813 · Cited by 58
MYC in Germinal Center‐derived lymphomas: Mechanisms and therapeutic opportunities
Bisso, A., Sabò, A., & Amati, B. B. (2019) · Immunological Reviews · doi:10.1111/imr.12734 · Cited by 57
Notch signaling in cancer: Complexity and challenges on the path to clinical translation
Ferreira, A. P. A., & Aster, J. C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.008 · Cited by 56
Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia
Zanwar, S., Abeykoon, J. P., Durot, É., King, R. L., Burbano, G. P., Kumar, S. K., Gertz, M. A., Quinquenel, A., Delmer, A. J., Gonsalves, W. I., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25697 · Cited by 56
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes
Scholze, H., Stephenson, R. E., Reynolds, R., Shah, S. B., Puri, R., Butler, S. D., Trujillo-Alonso, V., Teater, M. R., van Besien, H. J., Gibbs-Curtis, D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002580 · Cited by 56
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas
Heward, J. A., Koniali, L., D’Avola, A., Close, K., Yeomans, A., Philpott, M., Dunford, J. E., Rahim, T., Seraihi, A. A., Wang, J., et al. (2021) · Blood · doi:10.1182/blood.2020008743 · Cited by 56
Self-citationXu-Monette, Z. Y., Wei, L., Fang, X., Au, Q., Nunns, H., Nagy, M., Tzankov, A., Zhu, F., Visco, C., Bhagat, G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2949 · Cited by 56
Shah, S. B., Carlson, C. R., Lai, K., Zhong, Z., Marsico, G., Lee, K. M., Vélez, N. E. F., Abeles, E. B., Allam, M., Hu, T., et al. (2023) · Nature Materials · doi:10.1038/s41563-023-01495-3 · Cited by 55
PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice
Weber, J., Rosa, J. D. L., Grove, C. S., Schick, M., Rad, L., Baranov, O., Strong, A., Pfaus, A., Friedrich, M., Engleitner, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09180-3 · Cited by 55
Barraclough, A., Alzahrani, M. F., Ettrup, M. S., Bishton, M. J., Vliet, C. V., Farinha, P., Gould, C., Birch, S. E., Sehn, L. H., Sovani, V., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000251 · Cited by 55
Self-citationBolen, C. R., Klánová, M., Trněný, M., Sehn, L. H., He, J., Tong, J., Paulson, J. N., Kim, E., Vitolo, U., Rocco, A. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.227892 · Cited by 55
LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells
Jo, T., Nishikori, M., Kogure, Y., Arima, H., Sasaki, K., Sasaki, Y., Nakagawa, T., Iwai, F., Momose, S., Shiraishi, A., et al. (2020) · Blood · doi:10.1182/blood.2019002654 · Cited by 55
Bock, A. M., & Epperla, N. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01702-5 · Cited by 55
Wang, Y., Wenzl, K., Manske, M. K., Asmann, Y. W., Sarangi, V., Greipp, P. T., Krull, J. E., Hartert, K. T., He, R. L., Feldman, A. L., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0233-5 · Cited by 54
Smith, V. M., Dietz, A., Henz, K., Brücher, D., Jackson, R. A., Kowald, L., van Wijk, S. J. L., Jayne, S., Macip, S., Fulda, S., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.220525 · Cited by 54
Abdulla, M., Hollander, P., Pandzic, T., Mansouri, L., Ednersson, S. B., Andersson, P., Hultdin, M., Fors, M., Erlanson, M., Degerman, S., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25666 · Cited by 54
Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation
Yang, H., & Green, M. R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00272 · Cited by 54
Pittaluga, S., Nicolae, A., Wright, G. W., Melani, C. J., Roschewski, M. J., Steinberg, S. M., Huang, D., Staudt, L. M., Jaffe, E. S., & Wilson, W. H. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0009 · Cited by 54
Self-citationProposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma
Pedrosa, L., Fernández‐Miranda, I., Pérez-Callejo, D., Quero, C., Rodríguez, M., Martín, P., Gómez, S., González‐Rincón, J., Santos, A., Tarín, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80376-0 · Cited by 54
Frontzek, F., Staiger, A. M., Zapukhlyak, M., Xu, W., Bonzheim, I., Borgmann, V., Sander, P., Baptista, M. J., Heming, J.-N., Berning, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25405-w · Cited by 55
Self-citationGenomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma
Newman, A. M., Zaka, M., Zhou, P., Blain, A. E., Erhorn, A., Barnard, A., Crossland, R. E., Wilkinson, S., Enshaei, A., Zordi, J. D., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01444-6 · Cited by 54
Yang, H., Xiang, B., Song, Y., Zhang, H., Zhao, W., Zou, D., Lv, F., Guo, W., Liu, A., Li, C., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2020003698 · Cited by 54
Lew, T. E., & Seymour, J. F. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01295-3 · Cited by 54
The variant landscape and function of DDX3X in cancer and neurodevelopmental disorders
Gadek, M., Sherr, E. H., & Floor, S. N. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.06.003 · Cited by 53
Evrard, S., Péricart, S., Grand, D., Amara, N., Escudié, F., Gilhodes, J., Bories, P., Traverse‐Glehen, A., Dubois, R., Brousset, P., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.198572 · Cited by 53
Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma
Fornecker, L., Muller, L., Bertrand, F., Paul, N., Pichot, A., Herbrecht, R., Chenard, M., Mauvieux, L., Vallat, L. D., Bahram, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37273-4 · Cited by 53
Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles
Dubois, S., Tesson, B. M., Mareschal, S., Viailly, P., Bohers, É., Ruminy, P., Etancelin, P., Peyrouze, P., Copie‐Bergman, C., Fabiani, B., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.034 · Cited by 53
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL
Hartert, K. T., Wenzl, K., Krull, J. E., Manske, M. K., Sarangi, V., Asmann, Y. W., Larson, M. C., Maurer, M. J., Slager, S. L., Macon, W. R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0766-4 · Cited by 53
Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma
Liang, X., Song, X., Wu, J., Liu, D., Lin, B.-Y., Zhou, H., & Wang, L. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.67892 · Cited by 52
Heger, J., Mattlener, J., Schneider, J., Gödel, P., Sieg, N., Ullrich, F., Lewis, R. I., Mracica, T. B., Schwarz, R. F., Ruess, D. F., et al. (2023) · Blood · doi:10.1182/blood.2023022020 · Cited by 52
Biological heterogeneity in diffuse large B-cell lymphoma
Hilton, L. K., Scott, D. W., & Morin, R. D. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.11.006 · Cited by 52
HVEM network signaling in cancer
Šedý, J. R., & Ramezani-Rad, P. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.01.004 · Cited by 52
Carreras, J., Hiraiwa, S., Kikuti, Y. Y., Miyaoka, M., Tomita, S., Ikoma, H., Ito, A., Kondo, Y., Roncador, G., García, J. F., et al. (2021) · Cancers · doi:10.3390/cancers13246384 · Cited by 52
Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma
King, R. L., Hsi, E. D., Chan, W. C., Piris, M. A., Cook, J. R., Scott, D. W., & Swerdlow, S. H. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03404-6 · Cited by 52
Self-citationDLBCL: who is high risk and how should treatment be optimized?
Dabrowska-Iwanicka, A. P., & Nowakowski, G. S. (2023) · Blood · doi:10.1182/blood.2023020779 · Cited by 51
Primary large B-cell lymphomas of immune-privileged sites
Roschewski, M. J., Phelan, J. D., & Jaffe, E. S. (2024) · Blood · doi:10.1182/blood.2023020911 · Cited by 51
Self-citationGalimberti, S., Genuardi, E., Mazziotta, F., Iovino, L., Morabito, F., Grassi, S., Ciabatti, E., Guerrini, F., & Petrini, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00528 · Cited by 51
Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL
Baliñas-Gavira, C., Rodríguez, M. I., Andrades, Á., Cuadros, M., Álvarez-Pérez, J. C., Álvarez-Prado, Á. F., de Yébenes, V. G., Sánchez-Hernández, S., Fernández-Vigo, E., Muñoz, J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0919-5 · Cited by 51
Merdan, S., Subramanian, K., Ayer, T., Weyenbergh, J. V., Chang, A., Koff, J. L., & Flowers, C. R. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00404-0 · Cited by 51
Candelaria, M., & Dueñas‐González, A. (2021) · Therapeutic Advances in Hematology · doi:10.1177/2040620721989579 · Cited by 51
NF-κB and Human Cancer: What Have We Learned over the Past 35 Years?
Gilmore, T. D. (2021) · Biomedicines · doi:10.3390/biomedicines9080889 · Cited by 51
BTG1 mutation yields supercompetitive B cells primed for malignant transformation
Mlynarczyk, C., Teater, M. R., Pae, J., Chin, C. R., Wang, L., Arulraj, T., Barišić, D., Papin, A., Hoehn, K. B., Kots, E. D., et al. (2023) · Science · doi:10.1126/science.abj7412 · Cited by 50
Johnson, P., Balasubramanian, S., Hodkinson, B. P., Shreeve, S. M., Sun, S. H., Srinivasan, S. S., Steele, A. J., VERMEULEN, J. T., Sehn, L. H., & Wilson, W. H. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009389 · Cited by 50
Self-citationChen, F., Pang, D., Guo, H., Ou, Q., Wu, X., Jiang, X., Wei, X., Liu, S., Huang, L., Liang, Z., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3499 · Cited by 50
Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms
Mouhssine, S., Maher, N., Matti, B. F., Alwan, A., & Gaïdano, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063234 · Cited by 49
Stirm, K., Leary, P., Bertram, K., Núñez, N. G., Wüst, D., Boudesco, C., Verhoeyen, E., Zenz, T., Becher, B., Menter, T., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.2003533 · Cited by 49
Active DNA demethylation—The epigenetic gatekeeper of development, immunity, and cancer
Prasad, R. M., Yen, T. J., & Bellacosa, A. (2020) · Advanced Genetics · doi:10.1002/ggn2.10033 · Cited by 48
Insights into the tumor microenvironment of B cell lymphoma
Ng, W. L., Ansell, S. M., & Mondello, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02579-9 · Cited by 48
Richter syndrome: Novel insights into the biology of transformation
Parry, E. M., ten Hacken, E., & Wu, C. J. (2023) · Blood · doi:10.1182/blood.2022016502 · Cited by 48
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
Bolomsky, A., Ceribelli, M., Scheich, S., Rinaldi, K., Huang, D. W., Chakraborty, P., Pham, L., Wright, G. W., Hsiao, T., Morris, V. M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.026 · Cited by 48
Self-citationDeveloping a 3D B Cell Lymphoma Culture System to Model Antibody Therapy
Foxall, R. B., Narang, P., Glaysher, B. R., Hub, E., Teal, E. L., Coles, M. C., Ashton‐Key, M., Beers, S. A., & Cragg, M. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.605231 · Cited by 48
CAR T-Cell Therapy in the Older Person: Indications and Risks
Shouse, G., Danilov, A. V., & Artz, A. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01272-6 · Cited by 48
Li, J., Chin, C. R., Ying, H., Meydan, C., Teater, M. R., Xia, M., Farinha, P., Takata, K., Chu, C.-S., Jiang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47012-1 · Cited by 47
Wang, Z., Han, M., Wang, Y., Wang, N., Yang, Y., Shao, B., Miao, Q., Shi, Z., Yan, F., & Feng, S. (2025) · ACS Nano · doi:10.1021/acsnano.4c15761 · Cited by 47
Self-citationBoudesco, C., Verhoeyen, E., Martin, L., Chassagne‐Clément, C., Salmi, L., Mhaidly, R., Pangault, C., Fest, T., Ramla, S., Jardin, F., et al. (2018) · Blood · doi:10.1182/blood-2017-12-819706 · Cited by 47
The dangers of déjà vu: memory B cells as the cells of origin of ABC-DLBCLs
Venturutti, L., & Melnick, A. M. (2020) · Blood · doi:10.1182/blood.2020005857 · Cited by 48
Song, J. Y., Perry, A. M., Herrera, A. F., Chen, L., Skrabek, P., Nasr, M. R., Ottesen, R. A., Nikowitz, J., Bedell, V., Murata‐Collins, J. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2378 · Cited by 47
Self-citationYounes, S. F., Rojansky, R. B., Menke, J. R., Gratzinger, D. A., & Natkunam, Y. (2021) · Cancers · doi:10.3390/cancers13123021 · Cited by 47
Chen, R., Zhou, D., Wang, L., Zhu, L., & Ye, X. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207211072839 · Cited by 47
Frontzek, F., Karsten, I. E., Schmitz, N., & Lenz, G. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221103321 · Cited by 47
Genome-wide detection of human variants that disrupt intronic branchpoints
Zhang, P., Philippot, Q., Ren, W., Lei, W., Li, J., Stenson, P. D., Soler‐Palacín, P., Colobrán, R., Boisson, B., Zhang, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211194119 · Cited by 47
Marchesini, M., Gherli, A., Montanaro, A., Patrizi, L., Sorrentino, C., Pagliaro, L., Rompietti, C., Kitara, S., Heit, S., Olesen, C., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.04.002 · Cited by 46
Structure of S1PR2–heterotrimeric G 13 signaling complex
Chen, H., Chen, K., Huang, W., Staudt, L. M., Cyster, J. G., & Li, X. (2022) · Science Advances · doi:10.1126/sciadv.abn0067 · Cited by 45
Self-citationGenomic characterization of lymphomas in patients with inborn errors of immunity
Ye, X., Maglione, P. J., Wehr, C., Li, X., Wang, Y., Abolhassani, H., Deripapa, E. V., Liu, D., Borte, S., Du, L., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006654 · Cited by 45
Roschewski, M. J., & Hodson, D. J. (2023) · Haematologica · doi:10.3324/haematol.2021.278613 · Cited by 45
Self-citationMYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis
Yu, X., Li, W., Deng, Q., Liu, H., Wang, X., Hu, H., Cao, Y., Xu-Monette, Z. Y., Li, L., Zhang, M., et al. (2020) · Blood · doi:10.1182/blood.2020004918 · Cited by 45
Self-citationFlümann, R., Rehkämper, T., Nieper, P., Pfeiffer, P., Holzem, A. M. E., Klein, S., Bhatia, S., Kochanek, M., Kisis, I., Pelzer, B. W., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-19-0059 · Cited by 45
Li, C., Xia, J., Franqui-Machin, R., Chen, F., He, Y., Ashby, C., Teng, F., Xu, H., Liu, D., Gai, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146893 · Cited by 45
Shen, Y., Zhou, J., Nie, K., Cheng, S., Chen, Z., Wang, W., Wei, W., Jiang, D., Peng, Z., Ren, Y., et al. (2021) · Blood · doi:10.1182/blood.2021012327 · Cited by 45
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes
Noerenberg, D., Briest, F., Hennch, C., Yoshida, K., Hablesreiter, R., Takeuchi, Y., Ueno, H., Staiger, A. M., Ziepert, M., Asmar, F., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01053 · Cited by 44
Self-citationLoss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma
Wenzl, K., Manske, M. K., Sarangi, V., Asmann, Y. W., Greipp, P. T., Schoon, H. R., Braggio, E., Maurer, M. J., Feldman, A. L., Witzig, T. E., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0130-3 · Cited by 44
Berendsen, M. R., Stevens, W. B. C., van den Brand, M., van Krieken, J. H., & Scheijen, B. (2020) · Cancers · doi:10.3390/cancers12123553 · Cited by 44
Metadata
- Authors
- Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., Hodson, D. J., Xiao, W., Yu, X., Yang, Y., Zhao, H., Xu, W., Liu, X., Zhou, B., Du, W., Chan, W. C., Jaffe, E. S., Gascoyne, R. D., Connors, J. M., Campo, E., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Delabie, J., Rimsza, L. M., Tay Kuang Wei, K., Zelenetz, A. D., Leonard, J. P., Bartlett, N. L., Tran, B., Shetty, J., Zhao, Y., Soppet, D. R., Pittaluga, S., Wilson, W. H., & Staudt, L. M.
- Affiliations
- National Cancer Institute (US)
- National Institutes of Health (US)
- City Of Hope National Medical Center (US)
- BC Cancer Agency (CA)
- From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer...
- University of Würzburg (DE)
- Robert Bosch Hospital (DE)
- University Health Network (CA)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Alliance for Clinical Trials in Oncology (US)
- Washington University in St. Louis (US)
- Frederick National Laboratory for Cancer Research (US)
- ORCID
- Schmitz, Roland
- Wright, George W.
- Huang, Da Wei
- Phelan, James D.
- Wang, James Q.
- Roulland, Sandrine
- Kasbekar, Monica
- Young, Ryan M.
- Shaffer, Arthur L.
- Hodson, Daniel J.
- Xiao, Wenming
- Yu, Xin
- Yang, Yandan
- Zhao, Hong
- Zhou, Bin
- Chan, Wing C.
- Jaffe, Elaine S.
- Gascoyne, Randy D.
- Connors, Joseph M.
- Rosenwald, Andreas
- Ott, German
- Delabie, Jan
- Rimsza, Lisa M.
- Zelenetz, Andrew D.
- Leonard, John P.
- Bartlett, Nancy L.
- Tran, Bao
- Shetty, Jyoti
- Zhao, Yongmei
- Pittaluga, Stefania
- Wilson, Wyndham H.
- Staudt, Louis M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-12
- Volume
- 378
- Issue
- 15
- Pages
- 1396-1407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6010183
- OpenAlex
- W2797584152
- Cited by
- 2,241
- References
- 30
- Citations by year
- 2026: 193 · 2025: 271 · 2024: 320 · 2023: 339 · 2022: 317 · 2021: 302 · 2020: 250 · 2019: 191 · 2018: 53
- FWCI
- 153.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- National Cancer Institute Strategic Partnering to Evaluate Cancer Signatures (SPECS II) grant (5U01CA157581-05)
- Intramural Research Program of the NIH, National Cancer Institute
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- diffuse large B-cell lymphoma, genetic subtypes, B cell receptor signaling, NOTCH1 mutation, NOTCH2 mutation, EZH2 mutation, BCL2 translocation, CD79B mutation, germinal center B-cell-like lymphoma, therapeutic vulnerabilities, precision medicine, survival outcomes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Biopsy, Genotype, Humans, Mutation, Prognosis, Lymphoma, Large B-Cell, Diffuse, Sequence Analysis, DNA, Genetic Heterogeneity, Gene Expression Profiling, Epigenesis, Genetic, Kaplan-Meier Estimate, Transcriptome, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.